Investing.com -- Tempest Therapeutics Inc (NASDAQ:TPST) stock jumped 15.9% on Thursday after H.C. Wainwright upgraded the company from Neutral to Buy with a price target of $11.00.
The upgrade follows Tempest’s strategic pivot, announced in November 2025, involving the acquisition of four dual-targeting CAR-T programs from Factor Bioscience and Erigen LLC in an all-stock transaction. As part of this restructuring, existing shareholders will retain approximately 35% of the pro forma company with 100% warrant coverage.
Analyst Joseph Pantginis described the move as "making lemonade out of lemons," noting that the transaction provides Tempest with a critical cash runway extension to mid-2027. This extended timeline gives the company approximately 18 months to advance its new lead program, TPST-2003, through initial clinical milestones.
The deal also brings new leadership to Tempest, with Factor’s co-founder Dr. Matt Angel taking over as CEO. While the company plans to continue developing its legacy assets (amezalpat and TPST-1495), these programs will require additional financing or partnerships to move forward.
Pantginis characterized the strategic shift as "high-risk, high-reward" that "fundamentally resets" the investment thesis for Tempest. The analyst cited the validated nature of CAR-T therapy and positive early clinical data supporting the TPST-2003 program as key factors in the upgrade decision.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.


























